LAUSR

To the Editor: Systemic lupus erythematosus (SLE) is an treated with tacrolimus and followed up at 3 months or autoimmune disease involving multiple systems. In recent years, the therapeutic treat-to-target (T2T) strategy was recommended for SLE. The immunosuppressive drugs are the standard of care in SLE treatment. Tacrolimus was one of the calcineurin inhibitors which was recommended in the 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association recommendations for the management of lupus nephritis (LN). However, few studies have focused on tacrolimus for the management of various extra-renal SLE manifestations [Supplementary Table 1, http://links. lww.com/CM9/B122]. There are also no T2T data about tacrolimus in SLE. So, we conducted this single-center, prospective, real-world study to better clarify the efficacy and safety of tacrolimus in various SLE manifestations and provide T2T evidence for tacrolimus.